Technical Analysis for TRIB - Trinity Biotech plc

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. It offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as bacterial and viral diseases, and autoimmune disorders; products for the in-vitro diagnostic testing for haemoglobin A1c (HbA1c) used in the monitoring and diagnosis of diabetes; Hb variants for the detection of Hemoglobinapothies; and reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for detecting liver and kidney diseases, and haemolytic anaemia. The company also provides UniGold HIV, a POC diagnostic test, which is carried out in the presence of the patient to diagnose the presence of HIV antibodies in the patient. In addition, it sells raw materials to the life sciences industry and research institutes. Its customers include hospitals, clinical and reference laboratories, public health facilities, and other outreach facilities. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.